Roopa Industries Share Price
Sector: Biotechnology & Drugs
58.88 +1.39 (2.42%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
57.02
Today’s High
59.00
52 Week Low
47.26
52 Week High
114.90
Key Metrics
- Market Cap (In Cr) 46.47
- Beta 0.39
- Div. Yield (%) 0
- P/B 2.65
- TTM P/E 19.91
- Sector P/E 17.63
- D/E 0.02
- Open Price 57.3
- Prev Close 57.49
Roopa Industries Analysis
Price Analysis
-
1 Week4.45%
-
3 Months15.07%
-
6 Month-21.49%
-
YTD-19.51%
-
1 Year1.97%
Risk Meter
- 68% Low risk
- 68% Moderate risk
- 68% Balanced Risk
- 68% High risk
- 68% Extreme risk
Roopa Industries Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 120.69
- Selling/ General/ Admin Expenses Total
- 3.55
- Depreciation/ Amortization
- 0.85
- Other Operating Expenses Total
- 3.58
- Total Operating Expense
- 117.43
- Operating Income
- 3.26
- Net Income Before Taxes
- 2.72
- Net Income
- 2.03
- Diluted Normalized EPS
- 2.57
- Period
- 2025
- Total Assets
- 76.46
- Total Liabilities
- 58.96
- Total Equity
- 17.49
- Tangible Book Valueper Share Common Eq
- 22.24
- Period
- 2025
- Cashfrom Operating Activities
- -6.59
- Cashfrom Investing Activities
- 2.18
- Cashfrom Financing Activities
- 4.82
- Net Changein Cash
- 0.4
- Period
- 2024
- Total Revenue
- 70.43
- Selling/ General/ Admin Expenses Total
- 4.19
- Depreciation/ Amortization
- 0.87
- Other Operating Expenses Total
- 7.17
- Total Operating Expense
- 66.86
- Operating Income
- 3.57
- Net Income Before Taxes
- 2.17
- Net Income
- 1.52
- Diluted Normalized EPS
- 1.93
- Period
- 2024
- Total Assets
- 64.68
- Total Liabilities
- 49.21
- Total Equity
- 15.47
- Tangible Book Valueper Share Common Eq
- 19.67
- Period
- 2024
- Cashfrom Operating Activities
- -3.28
- Cashfrom Investing Activities
- 1.11
- Cashfrom Financing Activities
- 3.2
- Net Changein Cash
- 1.03
- Period
- 2023
- Total Revenue
- 76.17
- Selling/ General/ Admin Expenses Total
- 3.96
- Depreciation/ Amortization
- 0.89
- Other Operating Expenses Total
- 6.84
- Total Operating Expense
- 73.17
- Operating Income
- 3
- Net Income Before Taxes
- 1.81
- Net Income
- 1.35
- Diluted Normalized EPS
- 1.72
- Period
- 2023
- Total Assets
- 56.55
- Total Liabilities
- 42.61
- Total Equity
- 13.94
- Tangible Book Valueper Share Common Eq
- 17.73
- Period
- 2023
- Cashfrom Operating Activities
- 8.91
- Cashfrom Investing Activities
- -0.99
- Cashfrom Financing Activities
- -7.47
- Net Changein Cash
- 0.45
- Period
- 2022
- Total Revenue
- 51.21
- Selling/ General/ Admin Expenses Total
- 2.63
- Depreciation/ Amortization
- 0.93
- Other Operating Expenses Total
- 5.18
- Total Operating Expense
- 48.59
- Operating Income
- 2.62
- Net Income Before Taxes
- 1.36
- Net Income
- 1.02
- Diluted Normalized EPS
- 1.29
- Period
- 2022
- Total Assets
- 49.02
- Total Liabilities
- 36.44
- Total Equity
- 12.58
- Tangible Book Valueper Share Common Eq
- 16
- Period
- 2022
- Cashfrom Operating Activities
- 2.34
- Cashfrom Investing Activities
- 3.65
- Cashfrom Financing Activities
- -5.01
- Net Changein Cash
- 0.99
- Period
- 2021
- Total Revenue
- 28.61
- Selling/ General/ Admin Expenses Total
- 4.19
- Depreciation/ Amortization
- 0.81
- Other Operating Expenses Total
- 4.27
- Total Operating Expense
- 26.63
- Operating Income
- 1.98
- Net Income Before Taxes
- 0.93
- Net Income
- 0.72
- Diluted Normalized EPS
- 0.91
- Period
- 2021
- Total Assets
- 46.33
- Total Liabilities
- 34.77
- Total Equity
- 11.56
- Tangible Book Valueper Share Common Eq
- 14.7
- Period
- 2021
- Cashfrom Operating Activities
- -0.25
- Cashfrom Investing Activities
- 1.34
- Cashfrom Financing Activities
- -0.32
- Net Changein Cash
- 0.25
- Period
- 2020
- Total Revenue
- 27.65
- Selling/ General/ Admin Expenses Total
- 2.36
- Depreciation/ Amortization
- 0.76
- Other Operating Expenses Total
- 4.82
- Total Operating Expense
- 25.54
- Operating Income
- 2.11
- Net Income Before Taxes
- 0.8
- Net Income
- 0.37
- Diluted Normalized EPS
- 0.47
- Period
- 2020
- Total Assets
- 38.19
- Total Liabilities
- 27.39
- Total Equity
- 10.8
- Tangible Book Valueper Share Common Eq
- 13.73
- Period
- 2020
- Cashfrom Operating Activities
- 2.44
- Cashfrom Investing Activities
- 0.7
- Cashfrom Financing Activities
- -3.06
- Net Changein Cash
- 0.08
- Period
- 2019
- Total Revenue
- 30.15
- Selling/ General/ Admin Expenses Total
- 0.93
- Depreciation/ Amortization
- 0.57
- Other Operating Expenses Total
- 3.74
- Total Operating Expense
- 27.96
- Operating Income
- 2.19
- Net Income Before Taxes
- 0.79
- Net Income
- 0.6
- Diluted Normalized EPS
- 0.78
- Period
- 2019
- Total Assets
- 36.47
- Total Liabilities
- 26.04
- Total Equity
- 10.42
- Tangible Book Valueper Share Common Eq
- 13.25
- Period
- 2019
- Cashfrom Operating Activities
- 4.42
- Cashfrom Investing Activities
- -2.43
- Cashfrom Financing Activities
- -1.88
- Net Changein Cash
- 0.11
- Period
- 2025-03-31
- Total Revenue
- 29.83
- Selling/ General/ Admin Expenses Total
- 0.9
- Depreciation/ Amortization
- 0.19
- Other Operating Expenses Total
- 0.86
- Total Operating Expense
- 29.58
- Operating Income
- 0.25
- Net Income Before Taxes
- 0.74
- Net Income
- 0.42
- Diluted Normalized EPS
- 0.51
- Period
- 2025-03-31
- Total Assets
- 76.46
- Total Liabilities
- 58.96
- Total Equity
- 17.49
- Tangible Book Valueper Share Common Eq
- 22.24
- Period
- 2025-03-31
- Cashfrom Operating Activities
- -6.59
- Cashfrom Investing Activities
- 2.18
- Cashfrom Financing Activities
- 4.82
- Net Changein Cash
- 0.4
- Period
- 2024-12-31
- Total Revenue
- 30.73
- Selling/ General/ Admin Expenses Total
- 0.86
- Depreciation/ Amortization
- 0.26
- Other Operating Expenses Total
- 0.84
- Total Operating Expense
- 30.02
- Operating Income
- 0.71
- Net Income Before Taxes
- 0.96
- Net Income
- 0.76
- Diluted Normalized EPS
- 0.97
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 25.61
- Selling/ General/ Admin Expenses Total
- 0.9
- Depreciation/ Amortization
- 0.2
- Other Operating Expenses Total
- 0.75
- Total Operating Expense
- 24.17
- Operating Income
- 1.44
- Net Income Before Taxes
- 0.73
- Net Income
- 0.58
- Diluted Normalized EPS
- 0.74
- Period
- 2024-09-30
- Total Assets
- 76.86
- Total Liabilities
- 60.53
- Total Equity
- 16.33
- Tangible Book Valueper Share Common Eq
- 20.76
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 13.49
- Cashfrom Investing Activities
- 0.41
- Cashfrom Financing Activities
- -13.22
- Net Changein Cash
- 0.68
- Period
- 2024-06-30
- Total Revenue
- 34.51
- Selling/ General/ Admin Expenses Total
- 0.89
- Depreciation/ Amortization
- 0.2
- Other Operating Expenses Total
- 1.14
- Total Operating Expense
- 33.66
- Operating Income
- 0.85
- Net Income Before Taxes
- 0.3
- Net Income
- 0.27
- Diluted Normalized EPS
- 0.35
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 22.08
- Selling/ General/ Admin Expenses Total
- 0.94
- Depreciation/ Amortization
- 0.19
- Other Operating Expenses Total
- 1.78
- Total Operating Expense
- 21.46
- Operating Income
- 0.63
- Net Income Before Taxes
- 0.76
- Net Income
- 0.46
- Diluted Normalized EPS
- 0.57
- Period
- 2024-03-31
- Total Assets
- 64.68
- Total Liabilities
- 49.21
- Total Equity
- 15.47
- Tangible Book Valueper Share Common Eq
- 19.67
- Period
- 2024-03-31
- Cashfrom Operating Activities
- -3.28
- Cashfrom Investing Activities
- 1.11
- Cashfrom Financing Activities
- 3.2
- Net Changein Cash
- 1.03
- Period
- 2023-12-31
- Total Revenue
- 19.24
- Selling/ General/ Admin Expenses Total
- 1.09
- Depreciation/ Amortization
- 0.23
- Other Operating Expenses Total
- 1.86
- Total Operating Expense
- 18.58
- Operating Income
- 0.66
- Net Income Before Taxes
- 0.36
- Net Income
- 0.27
- Diluted Normalized EPS
- 0.34
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Roopa Industries Technical
Moving Average
SMA
- 5 Day57.37
- 10 Day58.59
- 20 Day61.4
- 50 Day59.28
- 100 Day60.42
- 300 Day69.81
Roopa Industries Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Crestchem
- 168.9
- 0.2
- 0.12
- 350
- 119.7
- 49.84
- Sandu Pharmaceuticals
- 49.8
- -0.41
- -0.82
- 69.5
- 43.75
- 48.18
- Roopa Industries
- 58.88
- 1.39
- 2.42
- 114.9
- 47.26
- 46.47
- Chandra Bhagat Pharma
- 52.3
- -5.7
- -9.83
- 90
- 46.15
- 39.46
- Gujarat Terce Laboratories
- 53
- 1.85
- 3.62
- 94.9
- 44.52
- 39.4
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Crestchem
- 18.47
- 6.74
- 43.55
- 8.53
- Sandu Pharmaceuticals
- 31.24
- 1.15
- 3.89
- 2.23
- Roopa Industries
- 22.91
- 2.65
- 9.8
- 1.91
- Chandra Bhagat Pharma
- 45.88
- 1.32
- 3.13
- 0.72
- Gujarat Terce Laboratories
- -
- 6.07
- -10.41
- -1.93
Roopa Industries Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 30-May-25
- Audited Results
- 14-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results
- 14-Aug-24
- Quarterly Results
- 30-May-24
- Audited Results
- 12-Feb-24
- Quarterly Results
- 14-Nov-23
- Quarterly Results
- 12-Aug-23
- Quarterly Results
- 30-May-23
- Audited Results
- 14-Feb-23
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 30-Sept-24
- 09-Sept-24
- AGM
- 30-Sept-23
- 13-Sept-23
- AGM



